ecrin-mdr-crcClinical2021RAS mutant colorectal cancerRas Mutant Colorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2726186China8ECRIN MDRNot yet recruitingfalseAn exploratory clinical study of fluzoparib combined with bevacizumab in the maintenance treatment of RAS mutant colorectal cancer after first-line chemotherapyInterventions: Experimental group:fluzoparib combined with bevacizumab Primary outcome(s): Progression-free survival Study Design: Single arm2021-08-152726186ChiCTR2100050106